Vision Preservation and Restoration Following a 6 Month Trial of GlaucoCetin

Primary Open Angle Glaucoma Clinical Trial

Official title:

A Prospective Randomized Controlled Trial of GlaucoCetin vs Placebo in Glaucoma Patients With Visual Field Loss.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04784234
• Other study ID #: IRB #2020-145
• Status: Recruiting
• Phase: N/A
• Start date: February 1, 2021
• Est. completion date: December 31, 2023

Study information

• Verified date: June 2022
• Source: Wills Eye
• Contact: Natasha N Kolomeyer, MD
• Phone: 215-928-3123
• Email: nkolomeyer[@]willseye.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is looking at changes in vision and visual function before and after a six month trial of a daily medical food called GlaucoCetin, formulated with ingredients to support and protect the optic nerve cells. Open angle glaucoma patients will be randomized to receive either a placebo or the medical food for 6 months. We hope to learn if this medical food can improve the vision of our glaucoma patients and to report the findings obtained to the general public.

Description:

The primary objective of this study is to evaluate the improvement in vision and visual function during a 6 month trial of GlaucoCetin versus placebo in patients with open angle glaucoma. The secondary objective is to evaluate change in quality of life, electrophysiologic response, and contrast sensitivity.

Procedures involved during participation include review of medical/ocular history, best corrected visual acuity, multiple Humphrey visual field testing 24-2 and 10-2 , Octopus G-Top, pattern electroretinogram (PERG), ocular coherence tomography (OCT), ocular coherence tomography angiography (OCTA), intraocular pressure (IOP), contrast sensitivity testing (CSV-1000), corneal hysteresis, biomicroscopy, fundus exam, disc photos, and serum testing.

To evaluate quality of life, included in testing is Compressed Assessment of Ability Related to Vision (CAARV). Responses to multiple surveys regarding vision related quality of life (GQL-15, Glaucoma Symptom Scale (GSS), National Eye Institute Visual Function Questionnaire 25 (NEI VFQ-25)) and diet (NHANES Dietary Screener) will be captured. Number of daily steps will be monitored at 2 intervals during the study using pedometers.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: December 31, 2023
• Est. primary completion date: February 28, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years to 80 Years

Eligibility

Inclusion Criteria:

• Age of 40 to 80 years

• Bilateral open angle glaucoma with reliable visual field defects (at least one eye with mean deviation (MD) between -4.00 to -10.00 decibels (dB) on Humphrey Visual Field 24-2.

• Group 1 (Peripheral): meets 1 hodapp-parrish-anderson (HPA) criteria for defect (3 contiguous points depressed on the pattern standard deviation (PSD) p <5%, one of which is depressed at p <1% level), and does not meet below paracentral criteria for Group 2.

• Group 2 (Central): at least 1 paracentral point repeatedly depressed at p<1% on 24-2. Also meets the HAP criteria outlined above.

• Visual acuity 20/40 or better in each eye

• Intraocular Pressure (IOP) controlled at 2 measurements >3 months

• Clear media

Exclusion Criteria:

• Known bleeding disorder

• History of epilepsy or on anti-seizure medication

• Uncontrolled hypertension or diabetes

• Uncontrolled IOP

• Eye pathology leading to inaccurate IOP measurement

• Visually significant retinal pathology affecting vision in past or active (such as diabetic retinopathy or age related macular degeneration)

• Non-glaucomatous optic neuropathy

• Visually significant cataract (worse then 2+ cataract, or what is determined visually clinically significant by physician)

• History of ocular trauma

• Selective laser trabeculoplasty or laser procedure within past 3 months

• Cataract surgery within past 3 months

• Incisional glaucoma surgery within 6 months

• Current use of nitroglycerin

• Current use of antiplatelet therapy besides aspirin (such as clopidogrel) or anticoagulation (such as warfarin)

• Current use of systemic steroids or immunomodulating agents such as methotrexate.

• Sensitivity or allergy to any ingredients in GlaucoCetin: Curcumin, L-Taurine, N-Acetyl Cysteine, Niacinamide, Ginkgo Biloba, Lipoic Acid, Citicoline, Grape Seed Extract, Green Tea Leaf Extract, Coenzyme Q10, Biotin, Natural Astaxanthin, flavonoid complex containing Fisetin, Quercetin, and Luteolin

• Recent change in systemic medications or vitamins

• Use of Biotin, Ginkgo Biloba, Citicoline within past 3 months (or any other Glaucocetin ingredients within 1 month)

• Unreliable visual fields

• Unwilling to take supplement or placebo for 6 months

Related Conditions & MeSH terms

• Glaucoma
• Glaucoma, Open-Angle
• Primary Open Angle Glaucoma

Intervention

Dietary Supplement:
• GlaucoCetin
GlaucoCetin, a medical food in capsule form, is FDA regulated and includes ingredients that have been shown to support and protect mitochondrial function of retinal ganglion cells. GlaucoCetin consists of a mixture of Curcumin, N-Acetyl Cysteine, Ginkgo Biloba Extract, Alpha-lipoic Acid, Citicoline, Grape Seed Extract, Green Tea Extract, and Coenzyme Q10. Additional ingredients include L-Taurine, Niacinamide, Biotin, Natural Astaxanthin, Fisetin, Quercetin, Luteolin, Proprietary Dragonberry Flavor Complex, Monk Fruit, Bitter Blocker Natural Flavor, Citric Acid, Silica Dioxide, Fibersol-2, L-Leucine. Many of these are known anti-inflammatory and antioxidant ingredients. A 6 month supply of capsules, made for this study, will be provided at randomization with the following instructions: Take 6 capsules by mouth once daily with food.

Other:
• Placebo
The placebo is an identical capsule to the GlaucoCetin, made for this study, with no nutritional value. A 6 month supply of capsules will be provided at randomization with the following instructions: Take 6 capsules by mouth once daily with food.

Locations

Country	Name	City	State
United States	Wills Eye Hospital, Glaucoma Research Center	Philadelphia	Pennsylvania

Sponsors (2)

Lead Sponsor	Collaborator
Wills Eye	Guardian Health Sciences, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Visual Field Mean Deviation	Improvement in visual field mean deviation, measured in decibels, will be compared before, during and after a 6 month trial of daily GlaucoCetin vs Placebo capsules.	3 hour examinations during a 6 month period
Secondary	Perceived Quality of Life Improvement	Improvement in participants perceived vision-related quality of life (GQL-15, Glaucoma Symptom Scale (GSS)	20 minute questionnaires during a 6 month period
Secondary	Perceived Quality of Life Improvement measured by National Eye Institute Visual Function Questionnaire 25 (NEI VFQ-25)	Improvement in participants perceived vision-related quality of life ( National Eye Institute Visual Function Questionnaire 25 (NEI VFQ-25))	20 minute questionnaires during a 6 month period